Novo Nordisk, Eli Lilly sued over GLP‑1 drugs and blindness
Published
AI-generated summary of the coverage listed below: Novo Nordisk and Eli Lilly face U.S. lawsuits alleging their GLP‑1 medications cause nonarteritic anterior ischemic optic neuropathy, a condition that damages the optic nerve and can lead to sudden, painless vision loss. The claims link the drugs to this eye disorder.
Covered by 1 outlet across the spectrum: 0% left, 100% center, 0% right.
Who is covering this story
- Center (1): Mint